RxDoctor Payments Data

Dianna Ohlman, NP

Family · Saint Peters, MONPI 1952560260

Payments from drug & device makers

$3,490in general payments, 2019–2025

Across 186 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$814
  • Novartis$267
  • Amgen$261
  • Lilly USA, LLC$250
  • AstraZeneca$239
  • Boehringer Ingelheim$223
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,490 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$53,587
Medicare patients
336
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$21,948
MounjaroTirzepatide16$18,277
XareltoRivaroxaban11$12,414
Albuterol Sulfate HfaAlbuterol Sulfate32$769
Omeprazole30$519
Fluticasone Propionate25$518
Atorvastatin Calcium81$450
Gabapentin19$417
Amlodipine Besylate64$411
Metoprolol Succinate34$378
Rosuvastatin Calcium32$364
Nystatin22$355
Levothyroxine Sodium33$319
Losartan Potassium45$295
Doxycycline Hyclate28$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$113$21,94818 claims
Lilly USA, LLCMounjaro$250$18,27716 claims
Johnson & JohnsonXarelto$29$12,41411 claims
Almatica Pharma LLCSertraline Hcl$21$8716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.

Other family in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →